Cardinal Health (CAH.US) put in a daily MACD golden cross above the zero line on September 1, DIF crossing above DEA — a signal that, after late August's pullback, reads as confirmation that the medium-term uptrend is resuming. It landed on a weak tape: the S&P 500 and the Dow both slipped, yet Cardinal Health closed about 2% higher for a second straight session and reclaimed its 5-, 10-, 20- and 30-day moving averages. Turnover was about USD 320 million, lighter than the active stretch in late August, leaving today's volume the open question.

Fundamentals provide the medium-term driver. Fiscal fourth-quarter results (quarter ended June 30), reported August 11, showed revenue of about USD 63.7 billion, up 6% year over year, and adjusted EPS of USD 2.91 against the USD 2.42 consensus. Management added USD 5 billion to its share buyback authorization and guided to adjusted EPS growth of 13% to 15% for fiscal 2027. It also said it now serves close to half of the logistics market for cell and gene therapies, a high-margin niche where it is nearly the only provider. The sell side responded quickly: Baird and Wells Fargo raised their price targets to USD 274 and USD 277 on August 12, and RBC Capital started coverage with an Outperform rating on August 19.

The short-term catalyst came from the September 1 tape. US Treasuries were sold off that session, and market pricing for a rate hike at the Federal Reserve's September 15-16 meeting briefly reached about 65%, according to Barchart's same-day recap. As the broad market slipped, investors rotated into healthcare's defensive names, and Cardinal Health moved higher in sympathy with CVS and Humana.

The chart points the same way as the news flow. After the late-August dip, the stock climbed back above its interwoven short- and medium-term moving averages, and the 5- and 10-day lines near USD 235 form the first support shelf. A golden cross above the zero line is a continuation signal out of consolidation, not an oversold bounce from below zero. The heat shows up in the momentum gauges: price is pressing the upper Bollinger band, the Commodity Channel Index (CCI) runs above 100, and volume on the up day contracted versus the prior sessions. The price-volume fit is not perfect, so whether the move extends toward the 52-week high set on August 11 depends on today's tape.

On balance the near-term bias is constructive. Raised guidance, analyst upgrades and defensive inflows line up on the same side. The risks sit in volume and rates. If turnover stays light, the rally will lack the force to clear overhead supply, and management has already flagged the Inflation Reduction Act's drug-price negotiations as a policy variable in the fiscal 2027 outlook. If rate expectations keep climbing toward the September 15-16 decision, valuation across healthcare distribution stays capped. Watch today whether volume re-expands and whether CVS, UnitedHealth and other peers follow Cardinal Health's lead. If volume fades again, that is the sign the bounce is capped rather than accelerating.

This content is for informational purposes only and does not constitute investment advice, a recommendation, or an offer or solicitation to buy or sell any security or capital markets product. It has been prepared without regard to your individual investment objectives, financial situation, or particular needs. Investing involves risk, including the possible loss of principal; past performance is not indicative of future results. Longbridge and its affiliates accept no liability for any loss arising from reliance on this material.